BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 12670557)

  • 1. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database.
    Freedland SJ; Presti JC; Amling CL; Kane CJ; Aronson WJ; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):736-41. PubMed ID: 12670557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ;
    Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
    Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
    Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
    Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
    J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era.
    Ung JO; Richie JP; Chen MH; Renshaw AA; D'Amico AV
    Urology; 2002 Sep; 60(3):458-63. PubMed ID: 12350484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
    Manoharan M; Bird VG; Kim SS; Civantos F; Soloway MS
    BJU Int; 2003 Oct; 92(6):539-44. PubMed ID: 14511029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomy.
    Barlow LJ; Badalato GM; Bashir T; Benson MC; McKiernan JM
    BJU Int; 2010 Jun; 105(12):1646-9. PubMed ID: 19863523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.